Small non-coding RNA biomarkers in sputum for lung cancer diagnosis

Yun Su¹, Maria A. Guarnera², HongBin Fang³ and Feng Jiang²*  

Abstract  
The early detection of lung cancer can reduce the mortality. However, there is no effective means in clinical settings for noninvasively detecting lung cancer. We previously developed 3 sputum miRNA biomarkers and 2 sputum small nucleolar RNA (snoRNA) biomarkers that can potentially be used for noninvasively diagnosing lung cancer. Here we evaluate the individual and combined applications of the two types of biomarkers in different sets of lung cancer patients and controls. Combined analysis of the miRNAs and snoRNAs has a synergistic effect with 89 % sensitivity and 89 % specificity, and may provide a useful tool for lung cancer early detection.

Background  
Non-small cell lung cancer (NSCLC), primarily caused by cigarette smoking, is the leading cause of cancer-related mortalities [1]. There are two major types of NSCLC: adenocarcinoma (AC) and squamous cell carcinoma (SCC). The early detection of NSCLC may decrease the mortality [1, 2]. However, there is no effective and noninvasive means for the early detection [3]. Sputum is a noninvasively and easily accessible body fluid that contains exfoliated bronchial epithelial cells [4]. Molecular study of sputum could detect the molecular abnormalities in the bronchial airways that reflect those existing in primary lung tumors, and thus provides a noninvasive approach for NSCLC detection [5].  

Small non-coding RNAs (ncRNAs) mainly consist of microRNAs (miRNAs) and small nucleolar RNAs (snoRNAs), and play an important role in the pathogenesis of various cancers [6–16]. There is significant interest in the development of the tumor-related ncRNAs as biomarkers for cancer diagnosis [17]. We have identified a panel of three sputum miRNA biomarkers (miRs-21, 31, and 210) with 82.9 % sensitivity and 87.8 % specificity and a panel of two snoRNA sputum biomarkers (snoRDs-66 and 78) with 74.6 % sensitivity and 83.6 % specificity for lung cancer early detection [18–20]. Since lung cancer is a heterogeneous disease featuring field defects in the airway of smokers [21, 22], a single biomarker type can’t achieve the sensitivity and specificity required for clinically diagnosing NSCLC. Because miRNAs and snoRNAs have highly and actively different roles in tumorigenesis, integrating the miRNA and snoRNA-based biomarkers may improve the performance of the biomarkers for NSCLC detection. Here we evaluate the individual and combined applications of the two different types of ncRNAs for the early detection of lung cancer.

Findings  
With a protocol approved by Institutional Review Board of the University of Maryland Medical Center Center, we collected sputum from 316 NSCLC patients and 528 cancer-free smokers. Of the 316 lung cancer patients, 103 were diagnosed with stage I NSCLC. We used the 103 stage I NSCLC patients as cases. From the cancer-free subjects, we randomly selected 117 individuals as control cases. The 103 stage I NSCLC cases and 117 cancer-free smokers were randomly split into a training set (Table 1) and an internal testing set (Table 2).

We determined expressions of the five ncRNAs (miRs-21, 31, and 210, and snoRDs-66 and 78) by quantitative reverse transcriptase PCR (qRT-PCR) in the sputum samples [18, 23–27]. The panel of three miRNAs (miRs-21, 31, and 210) and panel of two snoRNAs (snoRDs-66 and 78) was assessed in the training set (Table 1). We also calculated the area under the receiver operating characteristic curve (AUC) for the panels of miRNAs and snoRNAs, respectively (Table 2). The panel of miRNAs and snoRNAs was further assessed in the internal testing set (Table 2).
snoRNAs (snoRDs-66 and 78) had a receiver operating characteristic (ROC) curve (AUC) value of 0.90 and 0.86, respectively (Fig. 1). Interestingly, combined use of the five ncRNAs produced 0.94 AUC (Fig. 1), being significantly higher than that of the panel of three miRNAs (0.90) or the panel of two snoRNAs (0.86) ($p < 0.05$). Furthermore, combined analysis of the five ncRNAs had higher sensitivity (89.13 % vs. 82.61 % or 73.91 %) and specificity (89.09 % vs. 85.45 % or 83.64 %) compared with the individual panels (All $p < 0.05$). The expression level of the five ncRNAs was associated with smoking history and size of PN of participants (All $p < 0.05$). The expression level of sputum miR-21 was more closely related with AC ($p < 0.05$), whereas miR-210 was associated with SCC ($p < 0.05$). However, overall, the panel of the five ncRNA biomarkers didn’t exhibit special association with a histological type of the NSCLC cases, and the age, gender, ethnicity, and forced expiratory volume 1 (FEV1)/forced vital capacity (FVC) of the participants (All $p > 0.05$). The validation of the ncRNA biomarkers in a testing cohort confirmed that combined study of miRNAs and snoRNAs in sputum had a synergistic effect for the early detection of NSCLC.

### Table 1
Characteristics of lung cancer patients and cancer-free smokers of a training set

|                   | NSCLC cases ($n = 46$) | Controls ($n = 55$) | $P$-value |
|-------------------|------------------------|---------------------|-----------|
| Age               | 65.28 (SD 11.27)        | 67.65 (SD 11.34)    | 0.35      |
| Sex               |                        |                     | 0.38      |
| Female            | 18                     | 22                  |           |
| Male              | 28                     | 33                  |           |
| Race              |                        |                     | 0.08      |
| White             | 30                     | 36                  |           |
| African American  | 16                     | 19                  |           |
| Pack-years        | 44.79 (Range, 5–172)   | 43.45 (Range, 5–109)| 0.38      |
| FEV1/FVC          | 0.45–0.79              | 0.43–0.80           | 0.10      |
| Nodule size (cm)  | 4.79 (Range, 95.25)    | 1.29 (Range, 56.76) | <0.01     |
| Stage, all are stage I |                    |                     |           |
| Histological type |                        |                     |           |
| Adenocarcinoma    | 25                     |                     |           |
| Squamous cell carcinoma | 21                 |                     |           |

**Abbreviations:** NSCLC non-small cell lung cancer

### Table 2
Characteristics of lung cancer patients and cancer-free smokers of a testing set

|                   | NSCLC cases ($n = 57$) | Controls ($n = 62$) | $P$-value |
|-------------------|------------------------|---------------------|-----------|
| Age               | 64.26 (SD 12.37)        | 66.69 (SD 10.88)    | 0.36      |
| Sex               |                        |                     | 0.39      |
| Female            | 22                     | 23                  |           |
| Male              | 35                     | 39                  |           |
| Race              |                        |                     | 0.09      |
| White             | 37                     | 40                  |           |
| African American  | 20                     | 22                  |           |
| Pack-years        | 43.89 (Range, 5–170)   | 42.64 (Range, 5–112)| 0.39      |
| FEV1/FVC          | 0.46–0.78              | 0.44–0.79           | 0.09      |
| Nodule size (cm)  | 4.89 (Range, 96.22)    | 1.54 (Range, 54.89) | <0.01     |
| Stage, all are stage I |                    |                     |           |
| Histological type |                        |                     |           |
| Adenocarcinoma    | 31                     |                     |           |
| Squamous cell carcinoma | 26                 |                     |           |

**Abbreviations:** NSCLC non-small cell lung cancer
Conclusion
Combined study of the miRNAs and snoRNAs has higher sensitivity and specificity compared with a single type of the ncRNA biomarkers, providing a noninvasive approach for lung cancer early detection. Nevertheless, a prospective project is required for validating the utility.

Ethical statements
No concern.

Competing interests
The authors declare that they have no competing interests.

Acknowledgements
This work was supported in part by VA merit Award I01 CX000512, LUNGevity/Upstage Foundation Early Detection Award, a grant support from DeCesaris/Prout Cancer Foundation, and The University of Maryland Research and Innovation Seed Program (F.J.).

Author details

1. Department of Surgery, Jiangsu Provincial Hospital, Nanjing University of Chinese Medicine, 155 Hanzhong Rd., Nanjing 210029, China.
2. Department of Pathology, The University of Maryland School of Medicine, 10 South Pine Street, MSTF 7th floor, Baltimore, MD 21201-1192, USA.
3. Department of Epidemiology, University of Maryland School of Medicine, Baltimore, MD, USA.

Received: 18 February 2016 Accepted: 4 May 2016
Published online: 12 May 2016

References
1. Cancer Facts & Figures 2012. American Cancer Society (ACS). J Consum Health Intern. 2012;16:366–7.
2. Aberle DR, Adams AAA, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatzonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.
3. Patz JE, Pinsky P, Gatzonis C, Sicks JD, Kramer BS, Tammemagi MC, Chiles C, Black WC. Aberle DR. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2014;174:269–74.
4. Saccozamanno G, Saunders RP, Archer VE, Auerbach O, Kuschner M, Beckler PA. Cancer of the lung: the cytology of sputum prior to the development of carcinoma. Acta Cytol. 1965;9:143–23.
5. Hubers AJ, Prinsen CF, Sozzi G, Witte B, Thunnissen E. Molecular sputum analysis for the diagnosis of lung cancer. Br J Cancer. 2013;109:530–7.
6. Croce CM, Calin GA, miRNAs, cancer, and stem cell division. Cell. 2005;122:6–7.
7. Mei Y, Clark D, Mao N. Novel dimensions of piRNAs in cancer. Cancer Lett. 2013;336:45–52.
8. Mannoor K, Liao J, Jiang F. Small nucleolar RNAs in cancer. Biochim Biophys Acta. 1826;2012:121–8.
9. Mannoor K, Shen J, Liao J, Liu Z, Jiang F. Small nucleolar RNA signatures of lung tumor-initiating cells. Mol Cancer. 2014;13:104.
10. Mei YP, Liao JP, Shen J, Yu L, Liu BL, Liu L, Li RY, Li L, Dorsey SG, Jiang ZR, Katz RL, Yang JY, Jiang F. Small nucleolar RNA 42 acts as an oncogene in lung tumorigenesis. Oncogene. 2012;31:794–804.
11. Liao J, Yu L, Mei Y, Guanera M, Shen J, Li R, Liu Z, Jiang F. Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer. Mol Cancer. 2010;9:198.
12. Dong XY, Rodriguez C, Guo P, Sun X, Talbot JT, Zhou W, Petros J, Li Q, Vessella RL, Kibel AS, Stevens VL, Calle EE, Dong JT. snoRNA US05 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Hum Mol Genet. 2008;17:1031–42.
13. Su H, Xu T, Ganapathy S, Shadfan M, Long M, Huang TH, Thompson I, Yuan ZM. Elevated snoRNA biogenesis is essential in breast cancer. Oncogene. 2014;33:1398–408.
14. Williams GT, Farzaneh F. Are snoRNAs and snoRNA host genes new players in cancer? Nat Rev Cancer. 2012;12:848–8.
15. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:2861–7.
16. Deng G, Gui G. Noncoding RNA in oncogenesis: a new era of identifying key players. Int J Mol Sci. 2013;14:18319–49.
17. Hayes J, Peruzzi PJ, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20:460–9.
18. Shen J, Liao J, Guanera MA, Fang H, Cai L, Stass SA, Jiang F. Analysis of MicroRNAs in sputum to improve computed tomography for lung cancer diagnosis. J Thorac Oncol. 2014;9:33–40.
19. Xing L, Su J, Guanera MA, Zhang H, Cai L, Zhou R, Stass SA, Jiang F. Sputum microRNA biomarkers for identifying lung cancer in indeterminate solitary pulmonary nodules. Clin Cancer Res. 2015;21:1484–9.
20. Su J, Liao J, Gao L, Shen J, Guanera MA, Zhan M, Fang H, Stass-Feng Jiang SA, Jiang F. Analysis of small nucleolar RNAs in sputum for lung cancer diagnosis. Oncotarget. 2015;6:128–32.
21. Tang X, Shimematsu H, Bekele BN, Roth JA, Minna JD, Hong WK, Gazdar AF, Wistuba, II, EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithilium in lung cancer patients. Cancer Res. 2005;65:7568–72.
22. Solis LM, Behrens C, Raso MG, Lin HY, Kadara H, Yuan P, Galindo H, Tang X, Lee JJ, Kalhor N, Wistuba, II, Moran CA. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer. 2012;118:2889–99.

Fig. 1 Combined analysis of miRNAs and snoRNAs in sputum has a synergistic effect for lung cancer detection. a ROC curve of a panel of three sputum miRNA biomarkers (miRs-21, 31, and 210) shows an AUC of 0.90 for differentiating NSCLC patients from the cancer-free subjects in terms of sensitivity and specificity. b a panel of two snoRNA sputum biomarkers (snoRDs-66 and 78) creates an AUC of 0.86 for distinguishing NSCLC patients from the cancer-free subjects. c combined study of the three miRNAs and two snoRNAs in sputum yields 0.94 AUC, which is significantly higher than that of any single type of ncRNAs used alone (P < 0.05) for lung cancer detection.
23. Anjuman N, Li N, Guarnera M, Stass SA, Jiang F. Evaluation of lung flute in sputum samples for molecular analysis of lung cancer. Clin Transl Med. 2013;2:15.
24. Li N, Ma J, Guarnera MA, Fang H, Cai L, Jiang F. Digital PCR quantification of miRNAs in sputum for diagnosis of lung cancer. J Cancer Res Clin Oncol. 2014;140:145–50.
25. Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H, Alattar M, Deepak J, Stass SA, Jiang F. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer. 2010;67:170–6.
26. Xing L, Todd NW, Yu L, Fang H, Jiang F. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod Pathol. 2010;23:1157–64.
27. Yu L, Shen J, Mannoor K, Guarnera M, Jiang F. Identification of ENO1 As a Potential Sputum Biomarker for Early-Stage Lung Cancer by Shotgun Proteomics. Clin Lung Cancer. 2014;28:16–22.